Psoriasis News

Kelly Giffin's suffered with psoriasis for 27 years. She's tried almost every ointment and cream available for her elbows, legs, scalp and ears.

Q: Can you please tell me, who is singing the national anthem at the end of the Lasershow? Fantastic performance of the song.

An FDA advisory committee has voted to recommend the biologic drug Enbrel's approval to treat plaque psoriasis in some children and teens.

SILVER SPRING, Maryland - Johnson & Johnson's experimental drug ustekinumab should be approved for treating adults with moderate or severe psoriasis, a U.S. advisory panel unanimously ruled on Tuesday.Panel ...

A U.S. Food and Drug Administration advisory panel recommended Wednesday that the psoriasis drug Enbrel be approved for use in children who have moderate-to-severe forms of the skin disease.

By Susan Heavey

WASHINGTON (Reuters) - U.S. drug regulators are concerned about life-threatening complications in children taking Amgen Inc's drug Enbrel for psoriasis and other conditions, according to documents released on Monday.

Amgen, which markets the injectable drug with Wyeth, is seeking approval from the U.S. Food and Drug Administration to expand sales to children with moderate to severe forms of the skin condition. The drug is already approved as an arthritis treatment in adults and children.

By Lisa Richwine

WASHINGTON (Reuters) - An experimental psoriasis drug from Johnson & Johnson is effective at relieving symptoms but extended use may raise the risk of cancer, U.S. drug reviewers said in documents released on Friday.

"Long-term use of ustekinumab may lead to increased risk of tumor development in psoriasis patients," Food and Drug Administration reviewers wrote in an analysis prepared for an advisory panel that is set to discuss the drug next week.

A spokesman for J&J's Centocor unit said the risk of cancer was theoretical and the company planned to monitor long-term safety after approval.

I spent 20 years looking for a cure for my psoriasis - and found it in a most unlikely place By Guy Kennaway Last updated at 12:06 AM on 10th June 2008 [headerlinks Personal battle: Guy Kennaway aimed for the ...

Palomplantar Pustulosis, a form of pustular psoriasis appears to respond well to Amevive according to researchers at Wake Forrest University School of Medicine.

IVREA, Italy 5th June 2008 Creabilis Therapeutics SpA, an emerging specialty pharmaceutical company focused on dermatology, today announces that it has raised a total of 20 million in a Series A round of ...

According to the study, the majority of Dermatologists reported an increase in their use of biologics for the treatment of psoriasis in the past year, particularly in patients with moderate psoriasis.

For some people, psoriasis is little more than the repeated occurrence of mild itching, but others experience life long, uncomfortable and unattractive skin changes.

TSX VENTURE EXCHANGE: AVI QUEBEC CITY, May 30 /CNW Telbec/ - Advitech Inc. announces today its financial results for the first quarter ended March 31, 2008.

Main Category: Dermatology Also Included In: Clinical Trials / Drug Trials Article Date: 30 May 2008 - 2:00 PDT Provectus Pharmaceuticals, Inc.

The use of biologics is the focus of new guidelines for the management of mild to severe psoriasis and psoriatic arthritis released by the American Academy of Dermatology .